Rhythm Pharmaceuticals (RYTM) Leases: 2018-2025
Historic Leases for Rhythm Pharmaceuticals (RYTM) over the last 7 years, with Sep 2025 value amounting to $3.2 million.
- Rhythm Pharmaceuticals' Leases fell 11.98% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 11.98%. This contributed to the annual value of $3.5 million for FY2024, which is 345.20% up from last year.
- According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Leases is $3.2 million, which was down 3.19% from $3.3 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' Leases peaked at $3.7 million during Q2 2024, and registered a low of $670,000 during Q1 2024.
- Its 3-year average for Leases is $2.3 million, with a median of $3.2 million in 2025.
- As far as peak fluctuations go, Rhythm Pharmaceuticals' Leases plummeted by 38.42% in 2024, and later spiked by 402.54% in 2025.
- Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Leases stood at $1.5 million in 2021, then fell by 22.34% to $1.2 million in 2022, then crashed by 33.93% to $781,000 in 2023, then soared by 345.20% to $3.5 million in 2024, then declined by 11.98% to $3.2 million in 2025.
- Its Leases stands at $3.2 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.4 million for Q1 2025.